Skip to main content

Prostate Cancer Care Costs Vary by Treatment

 |  By jsimmons@healthleadersmedia.com  
   August 25, 2010

The short-term and long-term costs of prostate cancer care can vary considerably based on which treatment strategies men initially choose and receive, according to an online study in the journal, Cancer.

For most prostate cancer cases, costs were highest in the initial year of the diagnosis—then dropped sharply and remained steady over the next several years, researchers at Johns Hopkins University School of Medicine said. However, the patterns of costs over a five-year period varied widely in the short-term and long-term based on the initial treatment received.

Watchful waiting had the lowest initial costs ($4,270) and five-year total costs ($9,130). Initial treatment costs, though, were highest for patients who received hormonal therapy plus radiation ($17,474)—then followed by those receiving surgery ($15,197).

Hormonal therapy had the second lowest initial costs, but also had the highest five-year total costs ($26,896). "This demonstrates that treatments that may be less expensive in the short-term may have higher long-term costs," said Claire Snyder, PhD, of the Johns Hopkins School of Medicine and the Johns Hopkins Bloomberg School of Public Health, who led a team that reviewed early stage prostate-cancer cases from the Surveillance Epidemiology and End Results (SEER)-Medicare database.

Hormonal therapy plus radiation ($25,097) and surgery ($19,214) were found to have the second and third highest five-year total costs. When excluding the last 12 months of life—where the  patterns of costs are quite different in the period prior to death—total costs were highest for hormonal therapy plus radiation ($23,488) and hormonal therapy only ($23,199).

This SEER database combined cancer incidence and survival data from U.S. population-based cancer registries with Medicare administrative claims. Patients included 13,769 men aged 66 years or older who were diagnosed in 2000 and were followed for five years and divided into groups based on the treatment they received.

Janice Simmons is a senior editor and Washington, DC, correspondent for HealthLeaders Media Online. She can be reached at jsimmons@healthleadersmedia.com.

Tagged Under:


Get the latest on healthcare leadership in your inbox.